A review by County Durham and Darlington Foundation Trust (CDDFT) has found that more than 300 women treated at its breast unit suffered preventable harm, including at least 20 unnecessary mastectomies. The report highlights NHS breast unit unnecessary mastectomies as a serious breach of clinical governance.
The findings, disclosed to the BBC in 2024, have revived calls for a formal inquiry into the trust’s governance and raised broader questions about patient safety across NHS cancer services. Families and advocacy groups are demanding accountability, compensation and systemic reforms.
Investigators identified over 300 patients who experienced adverse outcomes while receiving breast‑cancer care at the CDDFT unit, which serves County Durham and Darlington in north‑east England. Among them, twenty women had their breasts removed despite no medical indication for the surgery. One of those women, Denise Howarth, spoke publicly about the trauma of an operation she says was unnecessary.
The trust has not released a detailed audit explaining how the surgeries occurred. Sources say the internal review stops short of naming specific diagnostic or decision‑making failures, leaving a gap in accountability. Both the BBC and The Guardian report that the trust’s statement provided only aggregate figures and an acknowledgement that “clinical governance” had broken down.
Without a clear account of the errors – whether mis‑diagnosis, faulty imaging or lapses in multidisciplinary review – the root cause remains uncertain. Health‑care experts note that breast‑cancer pathways rely on multiple checks, from radiology to pathology to tumour‑board discussion. A failure at any stage can cascade into irreversible treatment.
The scale of the harm has immediate implications for public confidence in NHS cancer care. Women facing a breast‑cancer diagnosis may now hesitate to trust specialist advice, potentially delaying presentation and treatment. The trust could face legal claims, and the financial liability may extend to NHS England if compensation schemes are pursued.
Parliamentary pressure is mounting. MPs have asked the Department of Health and Social Care to commission an independent review and to consider new safeguards for diagnostic accuracy. No policy change has been announced yet, but the story has been cited in recent debates about strengthening oversight of cancer services.
For the women affected, the impact is both physical and psychological. Beyond the loss of breast tissue, many report lasting anxiety, depression and a sense of betrayal by a system meant to protect them. Support services, including counselling and patient‑advocacy groups, have been mobilised, but survivors say resources are uneven and often insufficient.
The trust has pledged to work with external advisers to understand the failures and to develop a remediation plan. It has expressed “deep regret” to those harmed, though no timeline for compensation offers has been set.
As investigations continue, unanswered questions centre on how such a breach could persist undetected for years and what mechanisms will be put in place to prevent recurrence. Stakeholders are watching closely, waiting for a definitive report that can translate the current shock into concrete policy action and, ultimately, restore trust in the NHS’s ability to deliver safe cancer care.